Straits Times Index
3,301.96 +15.63 (+0.48%) S&P 500
4,218.76 +8.52 (+0.20%) Dow
33,421.85 +112.34 (+0.34%) Nasdaq
12,815.19 -39.61 (-0.31%) BTC-USD
24,317.48 +417.45 (+1.75%) CMC Crypto 200
575.17 +0.42 (+0.07%)
VRTX Oct 2022 280.000 put
| Previous close | 8.48 |
| Open | 8.30 |
| Bid | 8.70 |
| Ask | 10.30 |
| Strike | 280.00 |
| Expiry date | 2022-10-21 |
| Day's range | 8.30 - 9.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 163 |
- Motley Fool
Big Pharma Upheaval Coming -- This Stock Is Poised to Skyrocket, Anyway
There's a lot in this legislation, including a provision that will allow Medicare to directly negotiate the prices of the costliest drugs. The U.S. House of Representatives is expected to vote in favor of the bill later this week. President Joe Biden has already stated that he's ready to sign it into law.
- Zacks
CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates
CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.
- Motley Fool
2 Top Biotech Stocks Defying the Bear Market
Vertex Pharmaceuticals' shares have soared 24% year to date despite the macroeconomic headwinds in its way. The biotech owes that in part to its dominance in the market for drugs that treat the underlying causes of cystic fibrosis (CF), an area in which Vertex is the only game in town. Revenue and earnings continue to grow for Vertex thanks to its CF franchise.
